China plans to invest approximately 2 trillion yuan ($295 billion) over the next five years to develop data centers nationwide. This significant investment aims to bolster infrastructure, support digital growth, and enhance technological capabilities, positioning China as a major player in global data storage and management.

China is gearing up to invest a massive $295 billion to advance its artificial intelligence (AI) infrastructure and research. This ambitious initiative aims to position China as a global leader in AI technology by fostering innovation across industries such as healthcare, manufacturing, and transportation. The plan will support the development of core AI components, including chips, algorithms, and data centers, strengthening domestic capabilities and reducing reliance on foreign technology.

The government’s strategic funding is also geared toward talent cultivation and establishing cutting-edge research hubs. By bolstering AI development, China hopes to stimulate economic growth, create high-tech jobs, and enhance national security. This enormous investment signifies China’s commitment to becoming a dominant force in the rapidly evolving AI landscape and challenges other nations to keep pace with its technological ambitions.

Overall, China’s $295 billion AI buildout plan underscores its determination to harness artificial intelligence for economic and strategic advantages. As the country accelerates its technological investments, it aims to solidify its position as a global AI innovator, reshaping the future of digital transformation worldwide.

source

Other People are Reading

Hubert Marleau
Chairman & CEO

Ladies and gentlemen, I’m President declared of the assembly, and I will conduct this meeting in French and in English.

[Foreign Language] Ladies and gentlemen, good morning, and welcome to the — this Annual General and Special Meeting of the Shareholders of Nio Strategic Metals. My name is Hubert Marleau, and I have the pleasure of being the Chairman of the Board of Director and Chief Executive Officer of Nio Strategic Metals. I declare the assembly open.

I am accompanied by Jean-Sebastien Blanchette, our Chief Financial Officer; and Bruno Dumais, President and Chief Operating Officer, who will act as Secretary of this meeting; as well as the directors, Julie Lemieux, Christoph Ebeling, Hubert Vallee, Alexandre Triquet and Sylvain Menard.

[Foreign Language] For those of you who wish to address the assembly, we ask you to draw my attention by using the box provided for this purpose on the website. I would like to emphasize and remind you that only registered shareholders of the company as of May 13, 2026, or their proxy holders are entitled to ask question, propose and support resolution at this meeting. In order to follow a greater number of shareholders to participate in this meeting and to reduce the related costs, and we have decided to hold assembly by teleconference only. Shareholders were able to exercise their rights by filling out a proxy form in order to be used at the meeting, the proxy had to be received by the company’s transfer agent and registrar, Computershares Inc., on or before June 15, 2026. Please note that the voting will not be possible during this meeting.

Shares of uniQure N.V. skyrocketed more than 75 percent Wednesday, closing in on $47.49 after the gene therapy company announced a major regulatory advancement for its experimental treatment AMT-130 targeting Huntington’s disease. The surge reflects renewed investor optimism around the potential for the first disease-modifying therapy for the devastating neurological disorder.

uniQure stock opened sharply higher and maintained strong gains throughout the morning session on the Nasdaq. The move more than doubled the company’s market capitalization in a single trading day, erasing earlier setbacks and highlighting the high-stakes nature of biotech investments tied to clinical and regulatory milestones.

The catalyst was confirmation that the U.S. Food and Drug Administration has agreed uniQure can pursue a Biologics License Application using existing Phase I/II data from the AMT-130 program, supporting a path toward accelerated approval. This development reverses prior regulatory hurdles and accelerates timelines for potential market entry.

Regulatory Progress on AMT-130

AMT-130 is a one-time, AAV-based gene therapy designed to lower levels of the mutant huntingtin protein responsible for Huntington’s disease. The disorder affects an estimated 30,000 people in the United States with another 200,000 at risk, causing progressive motor dysfunction, cognitive decline and psychiatric symptoms with no approved disease-modifying treatments currently available.

Earlier Phase I/II data showed promising results, including a statistically significant 75 percent slowing of disease progression at 36 months in the high-dose cohort as measured by the composite Unified Huntington’s Disease Rating Scale compared to external controls. Additional functional improvements were noted across key endpoints.

The FDA’s updated position allows uniQure to submit a BLA potentially as early as the third quarter of 2026, pending final alignment. This follows patient advocacy efforts, including petitions with tens of thousands of signatures, and comes amid broader shifts in FDA leadership and priorities for rare disease therapies.

Company executives expressed confidence in the data package. The therapy uses a precision delivery approach directly into the brain, aiming to provide long-lasting benefits from a single administration.

Company Background and Pipeline

uniQure, headquartered in the Netherlands with significant U.S. operations, specializes in AAV gene therapies for rare and severe genetic diseases. Its platform has delivered approved therapies in hemophilia B and other areas, providing foundational experience for the Huntington’s program.

Beyond AMT-130, the company is advancing candidates in Fabry disease and other indications. Recent updates on AMT-191 for Fabry showed sustained enzyme activity improvements and patients discontinuing enzyme replacement therapy.

Financially, uniQure has faced typical biotech pressures with ongoing research and development costs. First-quarter 2026 results showed a net loss, but the regulatory clarity could open doors to partnerships, additional funding or commercialization revenue if approved.

Market Reaction and Analyst Views

The dramatic share price increase reflects the binary nature of biotech catalysts. Prior to Wednesday’s news, the stock had traded in a range influenced by earlier regulatory uncertainty and broader sector volatility. Analyst price targets vary widely, with some forecasting substantial upside if AMT-130 reaches the market.

Wall Street has generally maintained a positive stance on uniQure’s potential, citing the unmet need in Huntington’s and the strength of the clinical data. However, risks remain, including manufacturing scale-up, long-term safety monitoring and competition from other approaches in the gene therapy space.

Trading volume spiked significantly as retail and institutional investors reacted. The stock’s movement also lifted related names in the gene therapy and neurological disease sectors.

Broader Implications for Gene Therapy Field

Wednesday’s announcement underscores evolving FDA flexibility for serious rare diseases with strong surrogate or early clinical signals. Huntington’s represents a particularly challenging area due to its genetic basis and progressive nature, making any meaningful slowing of decline highly impactful.

Patient advocacy groups welcomed the news. Organizations like Help4HD have long pushed for accelerated pathways, viewing AMT-130 as a potential game-changer for families affected by the hereditary condition.

The development arrives as the gene therapy sector matures, with more products gaining approvals and real-world evidence accumulating. Challenges around cost, access and delivery methods persist, but successes like uniQure’s could encourage further investment.

Risks and Considerations

Despite the enthusiasm, hurdles remain before any potential approval. Full data review, manufacturing inspections and possibly additional confirmatory studies could influence timelines. Pricing and reimbursement discussions for one-time therapies often prove complex given the high upfront costs.

uniQure will need to demonstrate consistent safety and efficacy at commercial scale. Long-term follow-up data will be critical, as gene therapies can produce effects that evolve over years.

For investors, the volatility inherent in clinical-stage biotech remains pronounced. While today’s surge rewards risk-takers, future developments around clinical holds, competitive data or macroeconomic factors could drive sharp reversals.

Looking Ahead

uniQure plans further engagement with regulators and expects to provide additional updates on the BLA process in coming months. Positive momentum could also support partnership discussions or capital raises to fund commercialization preparations.

The Huntington’s community awaits more details, with hope that AMT-130 could transform care for a disease that has long lacked meaningful interventions. As the company advances toward potential approval, attention will turn to execution and the therapy’s real-world impact.

Wednesday’s trading action caps a period of anticipation for uniQure and highlights the sector’s capacity for rapid value shifts on regulatory news. As the gene therapy landscape evolves, uniQure’s progress with AMT-130 positions it as a key player in addressing one of medicine’s most challenging genetic disorders.

Retailer continues its store investment plans

Retail giant Matalan has seen its losses narrow as its CEO says it has “substantial” growth opportunities thanks to its loyal customer base.

The Merseyside-based group reported revenues of £987m for the 53 weeks to February 28, up slightly on the £985m seen last year, with online sales in particular rising 10%. But improved margins meant losses narrowed from £67m last year to £55m in 2026.

The group’s preferred EBITDA profitability measure rose 24% year-on-year to £69m, which the group credited to “higher sales volumes and improved margin rates” in a tough and competitive UK retail market.

The company also invested in its ongoing store upgrade programme and in technology and supply chain upgrades, with capital expenditure rising from £17m to £46m.

That momentum continued into the current financial year, with Matalan reporting Q1 revenue growth of 2% year on year, with adjusted EBITDA rising 45% to £14.9m.

Henrik Nordvall, CEO at Matalan, said: “My first few months as CEO have reinforced exactly why I chose to join Matalan. This is a business with a much-loved brand, loyal customers and significant potential, and I have been encouraged by the progress already underway. I have also been struck by the passion our colleagues have for the Matalan brand and the belief they have in its future.

“We delivered strong EBITDA growth and improved gross margin in the period, despite a challenging and highly competitive retail environment, all while continuing to invest in the areas that are driving growth. A major driver of that progress has been our continued focus on delivering everyday style, quality and value for customers, and it is encouraging to see the positive response to improvements in our product offer, the strong performance of our refreshed stores and continued momentum online.

“While we remain mindful of the wider environment, we have started FY27 strongly, with positive sales growth and continued market share gains – particularly in womenswear. What gives us confidence is the scale of opportunity still ahead of us. With a large and loyal customer base, significant untapped omnichannel opportunity and clear evidence that our strategy is working, we believe the long-term growth opportunity for Matalan remains substantial.”

Millennials planning for retirement may need to prepare for a vastly different real estate landscape.

According to new projections from National Association of Realtors (NAR) chief economist Lawrence Yun, the national median home price is on track to hit $1 million by 2050 — just as millennials reach the traditional retirement age.

“Essentially, in about 25 years the national median home price will be a million dollars,” Yun said at a conference in Washington, D.C., on Tuesday. “It may be hard to envision that, but back in 1990, the national median price was $90,000.”

MORTGAGE RATES TICK HIGHER, BUT BUYERS SHOW SIGNS OF CONFIDENCE

To illustrate the trajectory, Yun also noted that even historically expensive markets like San Francisco had a median home price of just $250,000 in 1990. The long-term forecast highlights a growing disparity between Americans who build home equity and those who remain in the rental market.

A “For Sale” sign sits outside a home in Rancho Cucamonga, California, on Saturday, May 9, 2026. (Getty Images)

“Homeowners will continue to build wealth, while renters are simply spinning their wheels,” Yun said.

America’s median sales price for existing homes was nearly $430,000 in May, according to Realtor.com data, up more than 2% from the previous month. Meanwhile, Zillow lists the average U.S. rent across all bedrooms and property types at $2,006 per month, up $6 from the prior month.

Yun also commented on the state of the economy, explicitly stating that he does not forecast an economic recession for the U.S. in 2026. He predicted mortgage rates would remain relatively flat, averaging 6.5% throughout 2026. Existing-home sales are projected to grow 4% this year, rebounding slightly from a 30-year low in 2025, when elevated rates slowed market activity.

Additionally, he expects stable economic footing, projecting nationwide job gains to hit 400,000 for the year.

Also on the panel was NAR deputy chief economist and Vice President of Research Jessica Lautz, who described a “wonky market” where inventory performance varies widely — even between neighboring properties.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

“You’ll list a home on the market, and sometimes it’ll sit for months. And sometimes it’s going to have multiple offers, and they can be next door to each other,” she said during Tuesday’s panel.

Despite overall housing affordability challenges, Lautz pointed out three specific buyer segments that remain highly active: baby boomers selling homes for the first time, young COVID-era buyers and lifestyle renters seeking larger backyards or additional living space.

READ MORE FROM FOX BUSINESS

This article was written by

Follow

Analyst’s Disclosure: I/we have a beneficial long position in the shares of KO, PEP, NVDA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Disclaimer: I am not an investment advisor or professional. This article is my own personal opinion and is not meant to be a recommendation of the purchase or sale of stock. The investments and strategies discussed within this article are solely my personal opinions and commentary on the subject. This article has been written for research and educational purposes only. Anything written in this article does not take into account the reader’s particular investment objectives, financial situation, needs, or personal circumstances and is not intended to be specific to you. Investors should conduct their own research before investing to see if the companies discussed in this article fit into their portfolio parameters. Just because something may be an enticing investment for myself or someone else, it may not be the correct investment for you.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.